AU2021305347A1 - Salts and forms of a WEE1 inhibitor - Google Patents
Salts and forms of a WEE1 inhibitor Download PDFInfo
- Publication number
- AU2021305347A1 AU2021305347A1 AU2021305347A AU2021305347A AU2021305347A1 AU 2021305347 A1 AU2021305347 A1 AU 2021305347A1 AU 2021305347 A AU2021305347 A AU 2021305347A AU 2021305347 A AU2021305347 A AU 2021305347A AU 2021305347 A1 AU2021305347 A1 AU 2021305347A1
- Authority
- AU
- Australia
- Prior art keywords
- degrees
- compound
- cancer
- range
- peak
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063049996P | 2020-07-09 | 2020-07-09 | |
| US63/049,996 | 2020-07-09 | ||
| PCT/US2021/070851 WO2022011391A1 (en) | 2020-07-09 | 2021-07-08 | Salts and forms of a wee1 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2021305347A1 true AU2021305347A1 (en) | 2023-02-16 |
Family
ID=79552745
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021305347A Pending AU2021305347A1 (en) | 2020-07-09 | 2021-07-08 | Salts and forms of a WEE1 inhibitor |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12606567B2 (https=) |
| EP (1) | EP4178960A4 (https=) |
| JP (2) | JP2023533040A (https=) |
| KR (1) | KR20230038523A (https=) |
| CN (1) | CN116323613A (https=) |
| AU (1) | AU2021305347A1 (https=) |
| BR (1) | BR112023000350A2 (https=) |
| CA (1) | CA3188737A1 (https=) |
| MX (1) | MX2023000333A (https=) |
| TW (1) | TWI896701B (https=) |
| WO (1) | WO2022011391A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020384291A1 (en) | 2019-11-15 | 2022-05-26 | Recurium Ip Holdings, Llc | Chiral synthesis of a tertiary alcohol |
| CN116462687B (zh) * | 2022-01-18 | 2025-01-07 | 江苏天士力帝益药业有限公司 | Wee1抑制剂及其制备和用途 |
| EP4469086A4 (en) * | 2022-01-25 | 2026-01-21 | Verastem Inc | POLYTHERAPY FOR THE TREATMENT OF ABNORMAL CELL GROWTH |
| JP2025525935A (ja) * | 2022-08-05 | 2025-08-07 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | 子宮漿液性がんを治療するためのｗｅｅ１化合物 |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| WO2025076311A1 (en) * | 2023-10-06 | 2025-04-10 | Zeno Management, Inc. | Solid forms of a wee1 inhibitor |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2338876A1 (en) * | 2009-12-22 | 2011-06-29 | LEK Pharmaceuticals d.d. | Tamsulosin adipate for pharmaceutical use |
| CA3071405A1 (en) | 2017-08-01 | 2019-02-07 | Recurium Ip Holdings, Llc | 1, 2 - dihydro- 3h- pyrazolo [3, 4 - d] pyrimidin -3 - one analogs |
| MX2020009372A (es) | 2018-03-09 | 2020-10-14 | Recurium Ip Holdings Llc | 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-onas sustituidas. |
| WO2020210320A1 (en) | 2019-04-11 | 2020-10-15 | Recurium Ip Holdings, Llc | Substituted l,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones |
| AU2020384291A1 (en) | 2019-11-15 | 2022-05-26 | Recurium Ip Holdings, Llc | Chiral synthesis of a tertiary alcohol |
| WO2021127039A1 (en) | 2019-12-20 | 2021-06-24 | Recurium Ip Holdings, Llc | Combinations |
| AU2020407070A1 (en) | 2019-12-20 | 2022-07-14 | Recurium Ip Holdings, Llc | Combinations |
| MX2022007623A (es) | 2019-12-20 | 2022-09-23 | Recurium Ip Holdings Llc | Combinaciones. |
| BR112022012280A2 (pt) | 2019-12-20 | 2022-08-30 | Recurium Ip Holdings Llc | Combinações |
| AU2021271844A1 (en) | 2020-05-15 | 2022-12-08 | Recurium Ip Holdings, Llc | Mono- and combination therapies |
| WO2021242667A1 (en) | 2020-05-28 | 2021-12-02 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Optical see-through head-mounted lightfield displays based on substrate-guided combiners |
| EP4153591A4 (en) * | 2020-06-11 | 2024-01-24 | Recurium IP Holdings, LLC | METHOD FOR PRODUCING WEE1 INHIBITOR COMPOUNDS |
| WO2022136916A1 (en) | 2020-12-22 | 2022-06-30 | Recurium Ip Holdings, Llc | Wee1 inhibitors and methods for treating cancer |
| AU2022259496A1 (en) | 2021-04-12 | 2023-10-12 | Recurium Ip Holdings, Llc | Wee1 compound for treating uterine serous carcinoma |
| WO2022251224A1 (en) | 2021-05-28 | 2022-12-01 | Recurium Ip Holdings, Llc | Wee1 inhibitors and methods for treating cancer |
| WO2022271731A1 (en) | 2021-06-23 | 2022-12-29 | Recurium Ip Holdings, Llc | Wee1 inhibitors and methods for treating cancer |
| WO2023064282A1 (en) | 2021-10-13 | 2023-04-20 | Recurium Ip Holdings, Llc | Combinations of wee 1 inhibitors and anti-cd47 antibodies. |
| WO2023076485A1 (en) | 2021-10-28 | 2023-05-04 | Recurium Ip Holdings, Llc | Combination therapies comprising wee1 inhibitors and dna damage response (ddr) inhibitors |
| EP4447965A4 (en) | 2021-12-15 | 2025-12-03 | Recurium Ip Holdings Llc | COMBINATIONS FOR TRIPLE THERAPY OF BCL-2 INHIBITORS, WEE-1 INHIBITORS AND OTHER CHEMOTHERAPEUTIC AGENTS |
| JP2024546569A (ja) | 2021-12-15 | 2024-12-26 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | がんに対するｗｅｅ１阻害剤 |
| KR20240119096A (ko) | 2021-12-15 | 2024-08-06 | 리커리엄 아이피 홀딩스, 엘엘씨 | 암 치료를 위한 병용 요법 사용 |
| JP2025525935A (ja) | 2022-08-05 | 2025-08-07 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | 子宮漿液性がんを治療するためのｗｅｅ１化合物 |
| EP4587026A1 (en) | 2022-09-15 | 2025-07-23 | Recurium IP Holdings, LLC | Combinations |
| TW202421151A (zh) | 2022-09-16 | 2024-06-01 | 美商瑞卡瑞恩Ｉｐ控股有限責任公司 | Ｗｅｅ１抑制劑及用於治療癌症之方法 |
| EP4615459A4 (en) | 2022-11-08 | 2026-04-29 | Zeno Man Inc | Intermittent dosing regimen for azenosertib in treating cancer |
| KR20250094718A (ko) | 2022-11-08 | 2025-06-25 | 제노 매니지먼트, 인크. | Wee1 억제제로 암을 치료하기 위한 예측 바이오마커로서 시클린 e1 상태의 용도 |
| TW202502354A (zh) | 2023-06-02 | 2025-01-16 | 美商薩諾管理公司 | 同源重組修復缺陷（ｈｒｄ）作為預測性生物標記以便使用ｗｅｅ１抑制劑治療癌症 |
| WO2025076311A1 (en) | 2023-10-06 | 2025-04-10 | Zeno Management, Inc. | Solid forms of a wee1 inhibitor |
| WO2025106635A1 (en) | 2023-11-15 | 2025-05-22 | Zeno Management, Inc. | Alteration of f-box and wd repeat domain containing 7 (fbxw7) gene as a predictive biomarker for treating cancer with wee1 inhibitors |
| WO2025179038A1 (en) | 2024-02-21 | 2025-08-28 | Recurium Ip Holdings, Llc | Wee1 inhibitors and methods for treating cancer |
| WO2025184572A1 (en) | 2024-03-01 | 2025-09-04 | Zeno Management, Inc. | Wee1 inhibitor combination therapy |
| WO2025188946A1 (en) | 2024-03-07 | 2025-09-12 | Recurium Ip Holdings, Llc | Wee1 inhibitors and methods for treating cancer |
| WO2025193930A1 (en) | 2024-03-14 | 2025-09-18 | Zeno Management, Inc. | Wee1 inhibitor combination therapy |
-
2021
- 2021-07-08 BR BR112023000350A patent/BR112023000350A2/pt unknown
- 2021-07-08 CN CN202180055999.8A patent/CN116323613A/zh active Pending
- 2021-07-08 CA CA3188737A patent/CA3188737A1/en active Pending
- 2021-07-08 EP EP21838389.1A patent/EP4178960A4/en active Pending
- 2021-07-08 MX MX2023000333A patent/MX2023000333A/es unknown
- 2021-07-08 KR KR1020237004679A patent/KR20230038523A/ko active Pending
- 2021-07-08 AU AU2021305347A patent/AU2021305347A1/en active Pending
- 2021-07-08 US US18/004,628 patent/US12606567B2/en active Active
- 2021-07-08 JP JP2023501229A patent/JP2023533040A/ja active Pending
- 2021-07-08 WO PCT/US2021/070851 patent/WO2022011391A1/en not_active Ceased
- 2021-07-09 TW TW110125370A patent/TWI896701B/zh active
-
2025
- 2025-09-22 JP JP2025156853A patent/JP2025181949A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230265097A1 (en) | 2023-08-24 |
| TWI896701B (zh) | 2025-09-11 |
| NZ796125A (en) | 2025-10-31 |
| MX2023000333A (es) | 2023-03-08 |
| US12606567B2 (en) | 2026-04-21 |
| JP2025181949A (ja) | 2025-12-11 |
| CA3188737A1 (en) | 2022-01-13 |
| CN116323613A (zh) | 2023-06-23 |
| BR112023000350A2 (pt) | 2023-03-28 |
| EP4178960A4 (en) | 2024-07-17 |
| WO2022011391A1 (en) | 2022-01-13 |
| JP2023533040A (ja) | 2023-08-01 |
| TW202216716A (zh) | 2022-05-01 |
| EP4178960A1 (en) | 2023-05-17 |
| KR20230038523A (ko) | 2023-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12606567B2 (en) | Salts and forms of a WEE1 inhibitor | |
| CN115335379B (zh) | 含螺环的喹唑啉化合物 | |
| JP7710223B2 (ja) | 置換ピロロトリアジン系化合物およびその医薬組成物並びにそれらの使用 | |
| WO2025076311A1 (en) | Solid forms of a wee1 inhibitor | |
| CN102295635B (zh) | 抗肿瘤药物四氢化萘酰胺类化合物及其药学上可接受的盐及制备方法和应用 | |
| WO2016090257A1 (en) | Salts and crystalline forms of 6-acetyl-8-cyclopentyl-5-methyl-2((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d] pyrimidin-7(8h)-one (palbociclib) | |
| JP2014533719A (ja) | アプレピタントｌ−プロリン溶媒和化合物−組成物及び共結晶 | |
| EP4045507A1 (en) | Salts and forms of an estrogen receptor modulator | |
| ES2970120T3 (es) | Sal de potasio monohidratada de un derivado de tienopiridona y su proceso de preparación | |
| RU2858658C2 (ru) | Соли и формы ингибитора wee1 | |
| EP4056559A1 (en) | Phenyl amino pyrimidine compound or polymorph of salt thereof | |
| WO2021047528A1 (zh) | 一个烟醇醚衍生物的马来酸盐及其晶型和应用 | |
| CN105753869B (zh) | 一种cdk抑制剂和mek抑制剂的共晶及其制备方法 | |
| CN105732642B (zh) | 一种cdk抑制剂和mek抑制剂的共晶及其制备方法 | |
| EP4631937A1 (en) | Crystalline form or amorphous form of oxoisoindole-5-formamide compound or salt and solvate thereof | |
| CN114127074A (zh) | 无定形乌帕拉尼单甲苯磺酸盐 | |
| TW202328138A (zh) | 稠合二環類衍生物的可藥用鹽、晶型及其製備方法 | |
| US20220204502A1 (en) | Crystal polymorphism of pi3k inhibitor and method for preparing same | |
| CN121181551A (zh) | (R)-3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的丙二酸盐及其晶型 | |
| CN121591827A (zh) | 3-羟基-5-孕烷-20-酮衍生物的新晶型及其制备方法和用途 | |
| HK40121338A (zh) | 一种嘧啶苯胺类化合物的晶型、制备方法及应用 | |
| CN117466898A (zh) | 氨基吡唑并嘧啶化合物的晶体 | |
| CN118891264A (zh) | 螺环胺类芳基磷氧化合物的晶型及其制备方法 | |
| CN116528866A (zh) | Fgfr4抑制剂的盐的晶型 | |
| WO2018187643A1 (en) | Novel forms of afatinib dimaleate |